News
The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...
The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback